{
    "url_original": "https://www.wsj.com/articles/biogen-cuts-price-for-alzheimers-drug-aduhelm-by-half-11640001661?mod=business_lead_pos3",
    "url": "biogen-cuts-price-for-alzheimers-drug-aduhelm-by-half-11640001661",
    "title": "Biogen Cuts Price for Alzheimer’s Drug Aduhelm by Half",
    "sub_head": "The drug has sold poorly since its approval in June due to concerns about its safety, effectiveness and cost",
    "category_1": "Business",
    "category_2": "Health Care",
    "image_1_url": "https://images.wsj.net/im-455260?width=860&height=573",
    "image_1": "im-455260.jpg",
    "time": "2021-12-20 07:01:00",
    "body": "Biogen Inc.  is slashing in half the price of its controversial new Alzheimer’s disease treatment, Aduhelm, in a bid to revive a product launch that has stalled in part because of a backlash over the drug’s cost.<br />The price cut will reduce the average annual cost of treatment to $28,200 a patient from the $56,000 the company set when the drug was approved in June, Biogen said Monday."
}